171 related articles for article (PubMed ID: 27353429)
1. The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
Joerger M; Finn SP; Cuffe S; Byrne AT; Gray SG
Expert Opin Ther Targets; 2016 Nov; 20(11):1339-1356. PubMed ID: 27353429
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of bacterial-specific Th1 and Th17 responses that are enriched in CXCR5
Ma QY; Huang DY; Zhang HJ; Wang S; Chen XF
Int Immunopharmacol; 2017 Nov; 52():305-309. PubMed ID: 28982050
[TBL] [Abstract][Full Text] [Related]
3. Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer.
Duan MC; Han W; Jin PW; Wei YP; Wei Q; Zhang LM; Li JC
Inflammation; 2015 Dec; 38(6):2156-65. PubMed ID: 26077695
[TBL] [Abstract][Full Text] [Related]
4. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.
Bayliss TJ; Smith JT; Schuster M; Dragnev KH; Rigas JR
Expert Opin Biol Ther; 2011 Dec; 11(12):1663-8. PubMed ID: 21995322
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
6. Association between Th17-related cytokines and risk of non-small cell lung cancer among patients with or without chronic obstructive pulmonary disease.
Liao C; Yu ZB; Meng G; Wang L; Liu QY; Chen LT; Feng SS; Tu HB; Li YF; Bai L
Cancer; 2015 Sep; 121 Suppl 17():3122-9. PubMed ID: 26331819
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
Dempke WC; Sellmann L; Fenchel K; Edvardsen K
Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for lung cancer: for whom the bell tolls?
Madureira P; de Mello RA; de Vasconcelos A; Zhang Y
Tumour Biol; 2015 Mar; 36(3):1411-22. PubMed ID: 25736929
[TBL] [Abstract][Full Text] [Related]
9. New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer.
Zarogoulidis P; Yarmus L; Zarogoulidis K
Ther Deliv; 2013 Oct; 4(10):1221-3. PubMed ID: 24116905
[No Abstract] [Full Text] [Related]
10. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
11. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
12. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.
Raychaudhuri SK; Saxena A; Raychaudhuri SP
Clin Rheumatol; 2015 Jun; 34(6):1019-23. PubMed ID: 25939522
[TBL] [Abstract][Full Text] [Related]
13. Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.
Genova C; Rossi G; Rijavec E; Biello F; Barletta G; Tagliamento M; Grossi F
Expert Opin Drug Saf; 2017 May; 16(5):573-585. PubMed ID: 28351171
[TBL] [Abstract][Full Text] [Related]
14. Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Rossi G; Tagliamento M; Dal Bello MG; Coco S; Vanni I; Boccardo S; Alama A; Grossi F
Expert Opin Investig Drugs; 2017 May; 26(5):551-561. PubMed ID: 28388262
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
16. The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases.
Tabarkiewicz J; Pogoda K; Karczmarczyk A; Pozarowski P; Giannopoulos K
Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):435-49. PubMed ID: 26062902
[TBL] [Abstract][Full Text] [Related]
17. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis.
Saadoun D; Garrido M; Comarmond C; Desbois AC; Domont F; Savey L; Terrier B; Geri G; Rosenzwajg M; Klatzmann D; Fourret P; Cluzel P; Chiche L; Gaudric J; Koskas F; Cacoub P
Arthritis Rheumatol; 2015 May; 67(5):1353-60. PubMed ID: 25604824
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy and Immunotherapy for Lung Cancer.
Naylor EC; Desani JK; Chung PK
Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
[TBL] [Abstract][Full Text] [Related]
19. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
